The House of Representatives voted this week to lock in six more years of Pentagon-backed psychedelics research and to write parts of a Trump-era executive order into federal statute, even as Republican leadership kept a separate marijuana enlistment waiver proposal off the floor entirely. Both measures moved as part of the Fiscal Year 2027 National Defense Authorization Act, which cleared the chamber 216-212 after the psychedelics provisions were folded into an en bloc package and approved by voice vote. The split outcome says something about where cannabis and psychedelics policy actually stand in Washington right now: adjacent issues, treated very differently depending on which lobby, which optics, and which committee chair is involved.
For operators watching from the cannabis retail side, none of this changes state-level compliance obligations overnight, but it does underline a pattern worth tracking. Federal lawmakers remain far more comfortable authorizing clinical research into psilocybin, MDMA and ibogaine for veterans than they are loosening drug-testing standards tied to military recruitment. That asymmetry matters for multi-state operators and ancillary vendors trying to read the room in Washington, since it suggests near-term federal movement is more likely to arrive through therapeutic and research channels than through recruitment or workforce policy. Meanwhile, dispensary operations in legal states continue running on their own compliance rails entirely separate from federal drug law, which is why back-office systems like POS software for Michigan cannabis retailers still carry the operational weight of seed-to-sale tracking, tax calculation and age verification regardless of what happens on Capitol Hill. POS software for Michigan cannabis retailers
What the NDAA Amendments Actually Do
The research extension, backed by a bipartisan group including Reps. Morgan Luttrell, Jack Bergman and Troy Carter, stretches the reporting window on DOD-funded psychedelics trials from three years to nine, pushing performance funding out to September 30, 2033. That program, first authorized in the 2024 NDAA under then-President Biden, lets active-duty service members with PTSD or traumatic brain injury access clinical trials involving psilocybin, MDMA, ibogaine, 5-MeO-DMT and certain plant-based therapies, backed by $10 million in initial funding. A second amendment goes further, codifying elements of Trump's April executive order by requiring the VA to name an official overseeing "emerging therapeutic interventions" within 90 days and to file recurring reports to Congress on ibogaine and psychedelic-assisted therapy progress.
The Cannabis Waiver Proposal That Didn't Move
Here's the catch: a parallel amendment from Reps. Dave Joyce and Dina Titus, which would have pushed the Air Force, Space Force and Marine Corps to adopt the same THC-related enlistment waiver systems already used by the Army and Navy, never got a floor vote. House Rules Committee leadership simply declined to let it advance. The Army's own April policy change, dropping the waiver requirement for a single marijuana or paraphernalia conviction, shows the services can move on this unilaterally when readiness pressure builds. But a chamber-wide mandate is a different animal politically, and it stalled again this cycle, just as a similar measure did last year despite passing the House.
A Right-to-Try Expansion Also Got Shut Out
A third proposal, from Reps. Madeleine Dean and Nancy Mace, would have carved out an exception in the Controlled Substances Act allowing physicians to administer Schedule I substances, including certain psychedelics, to patients facing life-threatening conditions under expanded right-to-try protections. FDA has already granted breakthrough therapy status to MDMA and psilocybin for serious mental health conditions, yet DEA still has no registration pathway for physicians to act on that designation. This amendment also failed to reach the floor, leaving that regulatory gap in place for now.
Why the Distinction Matters for the Cannabis Industry
For compliance teams and operators tracking federal cannabis reform signals, the lesson here is not subtle: therapeutic and research-framed psychedelics policy is finding bipartisan traction in a way that adult-use cannabis reform, or even modest military recruitment accommodations, still is not. DOD reaffirmed just this month that marijuana use remains prohibited for service members and civilian employees, even as federal rescheduling efforts continue elsewhere. Hemp-derived products, including CBD, remain barred on military installations under longstanding zero-tolerance guidance. None of this directly touches state-licensed dispensary operations, but it does shape the broader federal posture that MSOs, investors and payment providers have to factor into any assumption about the pace of change ahead.
